BBOT to merge with Helix II SPAC in $450M deal; public listing expected Q3 2025

BridgeBio Oncology Therapeutics, Inc.

Total proceeds ~$450M from Helix trust (~$196M) and $260M PIPE led by Cormorant, including Deerfield, Novo Holdings, Wellington.
Combined company to be named BridgeBio Oncology Therapeutics (BBOT), trading on Nasdaq under ticker BBOT.
Pro forma equity value ~$949M at $10.36/share assuming no redemptions; BBOT shareholders roll 100% equity.
Lead programs: BBO-8520 (KRAS G12C Phase 1), BBO-10203 (RAS-PI3Kα Phase 1), BBO-11818 (pan-KRAS Phase 1 starting H1 2025).
Transaction approved by both boards; expected close Q3 2025, subject to stockholder approvals and conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.